TOPICS
Demand Generation for Biotech & Pharma
DIRECT ANSWER
Demand generation is the set of marketing activities that build awareness, educate prospects, and create interest in a product before buyers actively evaluate vendors. It covers top-of-funnel content, paid media, events, and SEO, and is distinguished from lead generation by its focus on creating demand rather than capturing it. For Biotech & Pharma companies, this matters because Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch.
What demand generation means for Biotech & Pharma
The MLR bottleneck is the defining pain. Position AI-CMO as a pre-MLR content acceleration layer — draft variations auto-generated with reference tagging to approved label language, so reviewers approve faster. Integration with Veeva Vault PromoMats is table stakes for enterprise deals. Secondary angle: omnichannel orchestration for HCP journeys that synchronize rep calls, emails, and event invites without manual coordination.
For Biotech & Pharma teams the relevant marketing pains are: Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch; HCP segmentation is done manually in Excel — field reps don't have actionable, data-driven targeting for their territories; Congress season (ASCO, ADA, ACC) creates content demand spikes that small medical affairs teams cannot absorb; Patient support programs are marketed reactively rather than through proactive lifecycle journeys; KOL engagement tracking is scattered across MSL notes, CRM fields, and email threads with no unified view; Brand teams in different therapeutic areas duplicate research and creative work with no shared asset library. FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute
Demand Generation vs. Lead Generation
Demand generation and lead generation are related but distinct. Demand gen creates the market — it makes prospects aware a problem exists and that a category of solution addresses it. Lead generation captures intent that already exists, converting aware prospects into identifiable contacts via gated content, demo requests, or free trials. Most B2B marketing programs need both: demand gen without lead gen wastes reach, and lead gen without demand gen starves the top of funnel.
The practical boundary sits at the conversion event. Ungated content (blog posts, podcasts, LinkedIn videos, webinars with no registration wall) is demand gen. Gated whitepapers, contact forms, and product sign-up flows are lead gen. The current industry trend — accelerated since 2023 — is to ungate more content and invest in brand-level demand creation, because buyers research extensively before ever raising a hand.
Running demand generation for Biotech & Pharma with CoMo
CoMo's agents apply demand generation across HCP email, med-ed portals, LinkedIn, congresses/events, speaker programs, rep-triggered digital, patient advocacy partnerships for Biotech & Pharma companies — tuned to VP Commercial Marketing at mid-size pharma; Director of Marketing Excellence at specialty biotech; Head of Omnichannel at large pharma and run under your approval, alongside every other marketing function.
FAQ
Demand Generation for Biotech & Pharma — common questions
What is a realistic timeline to see results from demand generation?
Paid demand gen (LinkedIn, display) can drive pipeline in 30–90 days. Organic demand gen — SEO content, podcast, community — typically takes 6–18 months to compound into reliable pipeline. Most B2B teams underinvest in organic because the payback period exceeds a typical quarter's reporting cycle.
How does demand generation differ for Biotech & Pharma companies?
The fundamentals are the same, but Biotech & Pharma marketing carries specific constraints — Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch and FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute. CoMo adapts execution to that context automatically.
BUILT BY COMO'S AGENTS
This page was written by CoMo — the autonomous CMO.
CoMo runs every channel of your marketing on your live data. See it work on your brand.